Journal of Clinical Oncology, Vol 23, No 10 (April 1), 2005: pp. 2346-2357
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.00.240
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley,
John R. Wunderlich,
James C. Yang,
Richard M. Sherry,
Suzanne L. Topalian,
Nicholas P. Restifo,
Richard E. Royal,
Udai Kammula,
Don E. White,
Sharon A. Mavroukakis,
Linda J. Rogers,
Gerald J. Gracia,
Stephanie A. Jones,
David P. Mangiameli,
Michelle M. Pelletier,
Juan Gea-Banacloche,
Michael R. Robinson,
David M. Berman,
Armando C. Filie,
Andrea Abati,
Steven A. Rosenberg
From the Surgery Branch; Experimental Immunology and Transplantation Branch; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute; National Eye Institute, National Institutes of Health, Bethesda, MD
Address reprint requests to Steven A. Rosenberg, MD, PhD, Surgery Branch, National Cancer Institute, NIH, CRC 3-3940, 10 Center Dr MSC 1201, Bethesda MD 20892-1202; e-mail: sar{at}mail.nih.gov
 |
ABSTRACT
|
|---|
PURPOSE: We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma.
PATIENTS AND METHODS: Thirty-five patients with metastatic melanoma, all but one with disease refractory to treatment with high-dose interleukin (IL) -2 and many with progressive disease after chemotherapy, underwent lymphodepleting conditioning with two days of cyclophosphamide (60 mg/kg) followed by five days of fludarabine (25 mg/m2). On the day following the final dose of fludarabine, all patients received cell infusion with autologous tumor-reactive, rapidly expanded tumor infiltrating lymphocyte cultures and high-dose IL-2 therapy.
RESULTS: Eighteen (51%) of 35 treated patients experienced objective clinical responses including three ongoing complete responses and 15 partial responses with a mean duration of 11.5 ± 2.2 months. Sites of regression included metastases to lung, liver, lymph nodes, brain, and cutaneous and subcutaneous tissues. Toxicities of treatment included the expected hematologic toxicities of chemotherapy including neutropenia, thrombocytopenia, and lymphopenia, the transient toxicities of high-dose IL-2 therapy, two patients who developed Pneumocystis pneumonia and one patient who developed an Epstein-Barr virus–related lymphoproliferation.
CONCLUSION: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.
|
INTRODUCTION
|
|---|
Adoptive cell transfer (ACT) immunotherapy is based on the ex vivo selection of tumor-reactive lymphocytes, and their activation and numerical expansion before reinfusion to the autologous tumor-bearing host.1 Murine models of ACT have established the ability of this approach to mediate the regression of established cancers and have provided important principles to guide human studies.2-4In murine models, prior host immunosuppression can dramatically improve the antitumor effects of ACT therapy.5,6 Additional improvements can be achieved by the systemic administration of interleukin (IL) -2 or other cytokines to support the transferred cells, and concurrent immunization with inflammatory formulations of the tumor antigen recognized by the transferred cells.7,8
In the National Cancer Institute (NCI; Bethesda, MD) Surgery Branch, we have developed improved methods for the generation of human tumor-infiltrating lymphocytes (TILs) with antitumor activity9,10 and have administered these TILs in combination with prior immunosuppression and the administration of IL-2.11 We previously reported that six (47%) of 13 patients with IL-2 refractory metastatic melanoma treated with this combination experienced an objective partial response. Two of the responding patients exhibited a transient lymphocytosis composed primarily of the transferred, tumor-reactive TIL cells. These two patients further demonstrated a clonal repopulation of their immune systems, with more than 70% of their peripheral blood lymphocytes (PBLs) consisting of a single tumor reactive clone for over four months after treatment.
In the current study, we extend these results to report on the treatment of a total of 35 patients with refractory metastatic melanoma using selected, rapidly expanded TIL cultures and high-dose IL-2 therapy after nonmyeloablative but lymphodepleting chemotherapy. Eighteen (51%) of the 35 treated patients demonstrated an objective response to treatment, and eight others demonstrated a mixed or minor response. Some patients also exhibited symptoms of autoimmune melanocyte destruction including vitiligo or uveitis. The results and analysis reported here help elucidate many of the principles required for the immune-mediated destruction of established cancers.
|
PATIENTS AND METHODS
|
|---|
Patient Treatments and Clinical Assessment
Patients older than 18 years with stage IV melanoma who were negative for hepatitis B and C and HIV infection and had a good performance status and a life expectancy of at least 3 months were eligible for treatment on this protocol. All patients signed an institutional review board–approved consent and had melanoma that was histologically confirmed by pathologists at the Clinical Center, National Institutes of Health (Bethesda, MD). All patients had assessable disease (measurable disease on computed tomography scan or by physical exam) refractory to standard treatments including high-dose IL-2 therapy (except patient 31, who did not receive IL-2 before entry into this protocol). Five (14.7%) of the 34 patients who received high-dose IL-2 initially responded to IL-2 therapy alone, but then exhibited progressive disease and were enrolled on this protocol. Granulocyte colony-stimulating factor (G-CSF)–mobilized stem cells were obtained by leukapheresis from all patients and cryopreserved before initiation of chemotherapy in the event that patients did not reconstitute their hematopoetic system. Patients received nonmyeloablative lymphodepleting chemotherapy as previously described12,13 consisting of 2 days of cyclophosphamide (60 mg/kg) followed by 5 days of fludarabine (25 mg/m2). On the day following the final dose of fludarabine, patients received cell infusion with tumor-reactive lymphocytes and high-dose IL-2 therapy consisting of 720,000 IU/kg intravenously every 8 hours to tolerance as previously described.14,15 After enrollment of 15 patients, the protocol was amended through the institutional review process so that all subsequent patients who had MART-1–specific16 or gp100-specific17 TIL received vaccination with 1 mg MART-1:26-35(27L) or gp100:209-217(210M) peptide in incomplete Freund’s adjuvant (IFA) injected subcutaneously.
Patients' hematologic parameters were monitored daily by obtaining complete and differential blood counts, and by flow cytometric analysis of peripheral mononuclear cells. Patient response was assessed using standard radiographic studies and physical examination at four weeks following cell administration and at regular intervals thereafter. A complete response (CR) was defined as the disappearance of all clinical evidence of disease. A partial response (PR) was defined as a 50% or greater decrease in the sum of the products of perpendicular diameters of all measurable lesions for at least one month with no increase in any lesion and no new lesions. Appearance of any new lesion or greater than 25% increase in any lesion following a PR or CR was considered a relapse. A CR or PR was considered to be an objective response, and duration was measured from the initiation of treatment to the time of relapse. Patients with mixed or minor responses or progressive disease were considered nonresponders.
Patient Materials and Cell Lines
TIL cultures for treatment were generated as previously described.9 This clinical trial was not designed to predict response rates on an intent-to-treat basis. Our prior analysis of sequential melanoma biopsies from HLA-A2+ patients demonstrated that tumor specific activity was detectable in TILs from 29 (81%) of the 36 patients screened.9 In brief, the method for TIL generation involved the initiation of multiple independent cultures in 24 well plates, which were maintained at 0.8-1.5 x 106 cells/mL. When sufficient TILs were available, each culture was tested by cytokine-release assay for antigen specificity and tumor reactivity. Active TIL cultures were expanded to treatment levels using a rapid expansion protocol (REP) as previously described18,19 with OKT3 (anti-CD3) antibody (Ortho Biotech, Bridgewater, NJ) and IL-2 in the presence of irradiated, allogeneic peripheral-blood mononuclear cells from at least three different donors. The rapidly expanded cultures were typically maintained for 13 to 14 days before patient infusion, and were infused into the patient by intravenous administration over 30 minutes.
Immunologic Assays
TIL activity and phenotype were determined by analysis of cytokine secretion, flourescence activated cell scanning (FACS), and immunocytochemistry as previously described.9,20,21
Statistical Analysis
Significance of variation between groups was evaluated using a two-tailed Student t test assuming equal or unequal variance with P  .05 considered significant.
|
RESULTS
|
|---|
Patient Characteristics
Thirty-five patients with assessable metastatic melanoma who had TIL cultures that recognized autologous or HLA-matched tumor cells were eligible for treatment on this protocol. The demographic characteristics of this patient population are shown in Table 1. All but two patients (patients 34 and 35) were HLA-A*0201+. All patients had progressive disease after receiving multiple prior therapies before treatment on this protocol, including surgery and (except patient 31) high-dose IL-2 therapy, and 18 of the patients had progressive disease after receiving chemotherapy.
Each patient had one or more metastatic lesions resected for the generation of lymphocyte cultures and autologous tumor cell targets.9 The activity and specificity of three representative TIL cultures used for treatment are shown in Table 2. All TIL cultures that recognized allogeneic HLA-A2–matched melanoma cells were screened for recognition of MART-1:27-35 and gp100:209-217 peptides.
View this table:
[in this window]
[in a new window]
|
Table 2. Antigen Specificity and Activity of Representative TIL Cultures Infused for Patient Treatment (IFN , pg/mL)
|
|
Clinical Results
Individual treatments varied based on the growth rates of cells and patient tolerance of IL-2 administration and are summarized in Table 3. A mean of 6.3 x 1010 cells was infused (range, 1.1 to 16.0 x 1010), comprising from one to four independently expanded TIL cultures per patient.
Eighteen (51%) of the 35 patients experienced objective clinical responses to treatment (three CRs and 15 PRs); their sites of tumor regression and duration of response are listed in Table 4. Eight other patients (23%) experienced mixed or minor responses to treatment. Regression of metastatic melanoma in diverse anatomic locations was seen, including bulky cutaneous and subcutaneous disease; widespread nodal disease in peripheral or central locations (Fig 1A); liver metastases (Fig 1B); multiple sites including brain and axillary disease (Fig 1C); lung and lymph nodes (Fig 1D); and lung and subcutaneous sites (Fig 1E).
View larger version (154K):
[in this window]
[in a new window]
|
Fig 1. Lymphodepletion and adoptive cell transfer–induced regression of metastatic disease in diverse anatomic sites. (A) Axillary, pelvic and intraperitoneal metastases (patient 1); (B) extensive liver disease (patient 31); (C) brain and recurrent axillary metastases (patient 28); (D) multiple lung and pelvic metastases (patient 6); (E) lung and subcutaneous disease (patient 21). Pre, pretreatment.
|
|
Patients who were treated with lymphodepleting chemotherapy and ACT therapy and who experienced a minor or mixed response, who had stable disease after treatment, or who progressed after a PR were eligible for an additional course of treatment. Three patients experienced an objective clinical response after the second course of treatment (patients 2, 6, and 17). Fourteen other patients received more than one course of lymphodepleting chemotherapy followed by cell transfer and high-dose IL-2 therapy on NCI Surgery Branch protocols. Eight patients who had a mixed or minor response or stable disease after a first course of treatment were re-treated with a second course with the same or a different TIL, and high-dose IL-2 therapy, but did not achieve an objective clinical response after the second course. Six additional patients had received a primary course of lymphodepleting chemotherapy and high-dose IL-2 therapy with cell transfer in prior Surgery Branch protocols without achieving an objective response before their enrollment in this protocol. These cell treatments included administration of cloned T cells (n = 2), non–rapidly expanded TIL (n = 1), peripheral blood–derived cells (n = 1) or gene-modified cells (n = 2). Five of these six patients experienced an objective clinical response to their second cycle of nonmyeloablative chemotherapy that was administered with rapidly expanded TIL and high-dose IL-2 therapy. In all, eight (47%) of the 17 patients treated with a second course including nonmyeloablative chemotherapy and rapidly expanded TIL experienced an objective response, suggesting that multiple courses of treatment are justified in some patients.
In an attempt to identify characteristics of the administered treatments that could predict patient response, many parameters of treatment were compared between the responding and nonresponding patients (Table 5). Characteristics of the lymphocyte cultures were similar in the two groups, and despite comparison of a large number of variables, no statistical difference was detected in any measured parameter of the cultures. Peptide vaccination after cell transfer also had no apparent effect on treatment efficacy, with eight of 17 nonresponders receiving vaccines (three gp100 and five MART-1) and 10 of 18 responding patients receiving vaccine (three gp100 and seven MART-1). The only statistically significant difference was found to be the number of IL-2 doses tolerated (P = .03, Student t test not corrected for multiple comparisons), with the nonresponding patients receiving more doses (mean, 9.6 ± 0.7) than the responding patients (mean, 7.7 ± 0.5). This difference might reflect an increased capacity for cytokine production or pro-inflammatory activities of the infused lymphocytes in vivo in the responding patients that limited their tolerance to high-dose IL-2.
Thirteen of the patients who had an objective response to this treatment ultimately progressed at one or more sites after treatment. For nine of these patients, antigen expression by tumor cells was evaluated in pretreatment and recurrent lesions. Recurrent lesions from four patients did not express HLA-A2 and recurrent lesions from one other patient did not express the MART-1 protein (Table 6, Fig 2). These results suggest that ACT therapy exerted a strong selective pressure on the tumor in these patients, and that the transferred cells eliminated antigen-expressing tumor cells by an antigen-dependent mechanism. Ten nonresponding patients had immunocytologically assessable disease before and after treatment; one patient exhibited an apparent loss of antigen expression coincident with cell administration, and two patients had no expression of HLA-A2 before treatment (on retrospective analysis). Seven nonresponding patients expressed HLA, MART-1 and gp100 antigens.
View larger version (65K):
[in this window]
[in a new window]
|
Fig 2. Loss of antigen expression in post-treatment lesions. Tumor cells in pretreatement samples expressed all antigens; however, individual antigens were lost from recurrent lesions. A) MART-1 antigen expression was lost in a recurrent lesion from patient 10. B) HLA-A2 antigen was lost in the recurrent tumor from patient 28. m , macrophage.
|
|
Toxicity of Treatment
There were no treatment-related deaths. Hematologic toxicities due to the conditioning chemotherapy were transient, and included low RBC and platelet counts requiring transfusions in 34 and 29 patients, respectively (Table 7). Low absolute neutrophil counts (ANCs) and absolute lymphocyte counts, and the extended depression of CD4 lymphocyte counts were observed in most patients. Seven patients experienced opportunistic infections including herpes zoster (n = 3), Pneumocystis carinii (n = 2), and respiratory syncitial virus (n = 1). One patient (the only patient who was seronegative for EBV on entrance into the trial) who experienced greater than 90% regression of cancer and returned to normal function, developed an EBV lymphoproliferative disease four months after treatment and died of this lymphoma eight months later. Several nonhematologic grade 3 and 4 toxicities associated with the lymphodepleting chemotherapy were noted in patients treated with ACT therapy (Table 7). Thirteen patients experienced episodes of febrile neutropenia, and one patient developed cortical blindness secondary to progressive multifocal neuropathy, a rare toxicity associated with fludarabine. Patients also exhibited typical transient toxicities associated with high-dose IL-2 therapy, which were easily managed. There were no grade 3 or 4 toxicities attributable to the administration of antitumor lymphocytes. However, 17 patients exhibited autoimmune melanocyte destruction, including twelve patients with vitiligo, three patients with uveitis, and two patients with both vitiligo and uveitis. Uveitis was treated with topical corticosteroid eye drops and all patients' vision returned to normal. Autoimmune manifestations of treatment were not significantly correlated with objective antitumor responses, although the correlation for patients who received TIL specific for melanocyte differentiation antigens suggested a trend (two-tailed P = .06).
View this table:
[in this window]
[in a new window]
|
Table 7. Time in Hospital and Nonhematologic Grade 3 and 4 Toxicities Related to Lymphodepleting Chemotherapy and Cell Transfer
|
|
The chemotherapy administered before cell transfer induced a transient depression of neutrophil counts. Because of conflicting information concerning the immunosuppressive impact of G-CSF administration on lymphocyte recovery in allotransplant patients, ten consecutive patients in this study (patients 14 through 23) received cell transfer in the absence of G-CSF administration. No obvious difference in clinical response was observed (4 PR, 6 no response [NR] in the no–G-CSF group compared to 14 PR, 11 NR in the G-CSF group), but G-CSF administration significantly improved neutrophil recovery, as measured by time to recovery of ANC > 500/mm3 (Fig 3) and average ANCs during the recovery phase (not shown).
View larger version (16K):
[in this window]
[in a new window]
|
Fig 3. Granulocyte colony-stimulating factor (G-CSF) administration significantly improved the time to neutrophil recovery (two-tailed P < .03). The percentage of patients who had recovered neutrophil counts above 500/mm3 is graphed. ANC, absolute neutrophil count
|
|
Absolute lymphocyte counts reached their lowest point at a mean value of 17/mm3 (range, 0 to 58 lymphocytes/mm3) by the day of cell transfer (normal range > 460 cells/mm3). In some patients, a transient lymphocytosis that peaked within the first week after cell transfer was seen (Fig 4). Figure 5 shows the analysis of PBL subsets in patients from 1 month to more than 1 year after cell transfer. The average pretreatment CD4+, CD8+, and B-cell counts were within normal limits. However, by 30 to 60 days after treatment, the average CD4+ count fell to 137 cells/mm3, and remained below 200 cells/mm3 for the duration of the study. CD8+ cell counts transiently rose to a maximum of 835 cells/mm3 60 to 90 days after transfer, but decayed to normal levels over time. Like T cells, the B-cell compartment was transiently depleted by the chemotherapy, but B-cell levels returned to the normal range with a few months of treatment in most patients (not shown). Platelet recovery more than 30,000/mm3 and ANC values at normal levels were typically achieved within 2 weeks of cell transfer in the first course of treatment. Interestingly, 17 patients who received a second course of treatment exhibited a significant delay in recovery of platelets, with a median time to recovery increasing from 8 days to 11 days (two-tailed P < 3 x 10–5) and a small (approximately 1 day) delay in neutrophil recovery (two-tailed P = .03). The delayed hematologic recovery after multiple courses of treatment represents a potential impediment to the use of repeated courses of treatment in some patients, although no patient on this study experienced pancytopenia that required administration of their mobilized progenitor cells banked before treatment.
View larger version (9K):
[in this window]
[in a new window]
|
Fig 4. Absolute lymphocyte count (ALC) increased transiently in some patients after adoptive cell transfer. The maximum ALC for each patient within the first 8 days after cell transfer is plotted for all nonresponding patients (NR) and objective responders (OR) who had peak ALC values above a relatively high, arbitrarily chosen value of 1,000 lymphocytes/mm3.
|
|
View larger version (23K):
[in this window]
[in a new window]
|
Fig 5. CD8+ lymphocyte counts recovered more rapidly than CD4+ lymphocytes. Each symbol represents an individual patient. All available data is included, but measurements were not available for all patients at each time increment. Open symbols represent five patients who were treated with a prior course of lymphodepleting chemotherapy. Horizontal lines indicate normal limits. A) Recovery of CD4+ cells. B) Recovery of CD8+ cells. Bars represent mean values of all patients.
|
|
Persistence of Transferred Lymphocytes
The long-term persistence of tumor-reactive T cells from the transferred TIL was investigated using fluorochrome-labeled HLA-A2/peptide tetramers or T cell receptor beta chain variable region (TCR Vß) family specific antibodies. The use of TCR Vß family–specific antibodies to follow individual T cell clones is hampered by a lack of a specific antibody to approximately one half of all expressed TCR Vß families, and interpretation of results is also complicated by endogenous reconstituting lymphocytes that can express the same Vß as the clone of interest. Several of the patients who exhibited an objective response had received a TIL that contained a predominant T cell clone that was recognized by HLA tetramers or Vß antibodies. Previous reports11,22 demonstrated that a high frequency of the transferred, tumor-reactive clone was maintained in peripheral blood of a few patients for several weeks after cell transfer. We extended these results by evaluating PBLs from select responding patients sampled months to years after treatment. The relative percentage of the transferred tumor reactive clones derived from the TIL varied widely from patient to patient, and four of the five patients with assessable samples had evidence of long-term clonal persistence (Fig 6). The frequency of MART-1–reactive cells in the PBL of patient 28 changed from a pretreatment level below detection (< 0.1%) to 3.8% of circulating CD8+ cells by day 146 after treatment. Similarly, patient 16, whose administered TIL included a tumor reactive, Vß1-expressing clone (not shown) demonstrated an increase in circulating Vß1 cells from a pretreatment value of 4.2% to a level of 8.8% of circulating CD8+ cells 23 months after treatment. Patient 21 had extended persistence of a tumor-reactive Vß22-expressing clone, with an endogenous pretreatment Vß22 level of 3.9% that increased 403 days after administration of a Vß22-containing TIL to 25.5% of circulating CD8+ cells. Most strikingly, 810 days after treatment, a MART-1–reactive, Vß7-expressing clone from the TIL of patient 10 comprised more than 66% of his circulating CD8+ lymphocytes. We are currently investigating a potential correlation between long-term tumor antigen–reactive lymphocyte persistence and tumor regression in patients treated with ACT using sensitive and quantitative nucleotide sequence based approaches including random amplification of cDNA ends (5'-RACE) analysis.
View larger version (47K):
[in this window]
[in a new window]
|
Fig 6. Transferred cells persisted for extended time in responding patients. Each tumor-infiltrating lymphocyte administered on day 0 contained a tumor reactive clone with the indicated T-cell receptor beta chain variable region (Vß) expression or HLA-A2/MART-1-26-35 (27L) tetrameter (A2/MART-1) –binding. The percentage of CD8+ cells recognized by the indicated reagent is indicated. Pre, pretreatment peripheral blood lymphocytes (PBL). Post, PBL on the day indicated after cell transfer.
|
|
|
DISCUSSION
|
|---|
The administration of ACT therapy and high-dose IL-2 therapy following lymphodepleting chemotherapy resulted in objective clinical responses in 18 of 35 patients with metastatic melanoma, including 34 patients who were refractory to treatment with high-dose IL-2. Thirteen of the 18 responding patients were also refractory to chemotherapy. Metastatic disease at numerous anatomic sites was susceptible to this therapy, including cutaneous lesions, bulky nodal disease, and visceral, brain, and bony metastases. The toxicities associated with this treatment included the expected toxicities of high-dose IL-2 therapy and the hematologic suppression associated with lymphodepleting chemotherapy; these were mostly transient and readily managed by standard supportive techniques.
Autoimmunity directed against normal melanocytes was observed in nine (75%) of the twelve patients who were treated with T-cell cultures that recognized melanocyte differentiation antigens and who experienced objective tumor regression. Melanocyte destruction in the skin commonly resulted in vitiligo in the responding patients. Similarly, anterior uveitis was detected in four responding patients, and was controlled with corticosteroid eye drops. A link between successful immunotherapy and the onset of autoimmunity has been noted in several clinical immune-based therapies,15,23,24 as well as preclinical immunotherapy models,25 suggesting a strong link between the mechanisms of tumor regression and autoimmune attack on normal tissues. The nature of the melanoma antigen targeted by TIL did not predict the outcome of treatment. Shared tumor antigens such as MART-1 that are expressed by nonmalignant tissues were as effective for targeting melanoma destruction as unique antigens expressed only by the tumor cells. This observation suggests that peripheral mechanisms of self-tolerance (ie, other than thymic deletion) can inhibit the endogenous immune response to tumor, and need to be overcome to induce clinically relevant antitumor responses.
The current protocol incorporated several changes compared to our prior efforts at ACT of patients with melanoma. Improved approaches were developed for the generation of tumor-reactive lymphocyte cultures that often contained multiple clonotypes and a mixture of CD4+ and CD8+ cells.9 In the current trial, 31 treatments contained cells that were selected for tumor recognition and rapidly expanded with OKT3 only a single time, and five treatments (1 PR and 4 NR) contained cells expanded with OKT3 more than once. These cultures contrasted with the unselected TIL26 or the highly selected cloned CD8+ lymphocytes13,18 we administered in prior trials. In previous trials with cloned CD8+ lymphocytes for ACT, the generation of large numbers of cloned cells required at least three expansions mediated by OKT3. The decreased proliferative potential of the cells used in prior trials that were rapidly expanded multiple times in vitro may have accounted for the poor persistence of these cells after cell transfer and their failure to cause tumor regression. A second important change we incorporated into the current protocol was the administration of a conditioning chemotherapy regimen before the cell infusion. This chemotherapy regimen contained agents with little antimelanoma activity and was designed to deplete endogenous lymphocytes before the cell transfer. The role of lymphodepletion in augmenting the antitumor function of adoptively transferred lymphocytes is an area of active investigation. Two potential mechanisms have been proposed based on studies in preclinical models: the elimination of suppressor T cells,27 or the decreased competition by endogenous lymphocytes for homeostatic regulatory cytokines such as IL-7 or IL-15.7,28,29 The observation of lymphocytosis in some responding patients (Fig 4), together with the suggestion of antitumor T-cell persistence in patients with extended responses (Fig 6) offers hints as to the requirements for successful tumor treatment by ACT therapy. These observations suggest that the capacity for T-cell proliferation in vivo and the transfer into a lymphodepleted host are important determinants of efficacy. More research into these aspects of cell transfer therapy is warranted.
Several variations in administered treatments did not apparently impact the treatment efficacy. Although administration of G-CSF has been reported to be immuno-suppressive in patients undergoing allotransplantation of stem cells,30,31 no statistical difference in the response rate was observed in the small, nonrandomized patient populations in this study. Similarly, there were no apparent immunologic or clinical differences between patients receiving a peptide vaccine after cell transfer and those patients who did not receive vaccination. Other aspects of treatment, which are active areas of investigation, include the route of cell administration (intra-arterial v intravenous32), and the dose and schedule of IL-2 administration.33
Some of the patients reported here had extensive tumor regression, but eventually recurred at pre-existing or new sites. Immunocytochemical analysis of pretreatment and recurrent lesions demonstrated a loss of antigen expression by the recurrent tumor in five (55%) of nine patients who relapsed after an objective response. In two patients (patients 2 and 28) the loss of HLA class I antigens observed by immunocytochemical analysis was confirmed by in vitro functional analysis. Melanoma cell lines derived from recurrent tumor biopsies of these patients demonstrated loss of HLA expression (due to mutation of the beta2-microglobulin gene in one patient) and failure to stimulate antigen-specific T cells (not shown). In one patient treated with MART-1 reactive cells, the expression of MART-1 protein was selectively decreased while other melanoma differentiation antigens including gp100 were not affected. These results demonstrate that the transferred T cells exerted a strong selective pressure on the tumor in vivo, and confirm that the antitumor effects of this treatment are antigen mediated.
In summary, the results presented here establish that ACT therapy can impact bulky metastatic melanoma that is refractory to other treatments including high-dose IL-2 therapy and chemotherapy. Fifty-one percent of the patients experienced objective tumor responses with durations from 2 months to more than 2 years, including three patients (9%) with an ongoing complete response. Many aspects of this treatment have the potential to be improved by additional studies of the basic scientific principles of immune-mediated tumor rejection and the optimization of their clinical application. Current studies in our laboratory are focused on the logistical aspects of generating autologous cell–based patient treatments, the genetic modification of lymphocytes with T-cell receptor genes and cytokine genes to change their specificity or improve their persistence, and the administration of antigen specific vaccines to augment the function of the transferred cells.
|
Authors' Disclosures of Potential Conflicts of Interest
|
|---|
The authors indicated no potential conflicts of interest.
|
Acknowledgment
|
|---|
We are grateful for the expert cell culture, technical, and data processing assistance provided by Linda Parker, Azam Nahvi, Thomas Shelton, Amy Hubicki, Kevin O'Regan, Mary Ganges, Patti Fetsch, and Melissa Corbett. We are also grateful for the expert patient care provided by the immunotherapy nurses and fellows of the Surgery Branch, the nurses and staff of 2 East of the Clinical Center, National Institutes of Health, and the Surgical Intensive Care Units of the Center for Cancer Research, the NCI, and Michael Bishop.
|
NOTES
|
|---|
Authors' disclosures of potential conflicts of interest are found at the end of this article.
|
REFERENCES
|
|---|
1. Dudley ME, Rosenberg SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675, 2003[CrossRef][Medline]
2. Eberlein TJ, Rosenstein M, Rosenberg SA: Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 156:385-397, 1982[CrossRef]
3. Overwijk WW, Tsung A, Irvine KR, et al: gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277-286, 1998[Abstract/Free Full Text]
4. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986[Abstract/Free Full Text]
5. Cheever MA, Greenberg PD, Fefer A: Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 125:711-714, 1980[Abstract]
6. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063-1074, 1982[Abstract/Free Full Text]
7. Klebanoff CA, Finkelstein SE, Surman DR, et al: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101:1969-1974, 2004[Abstract/Free Full Text]
8. Overwijk WW, Theoret MR, Finkelstein SE, et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569-580, 2003[Abstract/Free Full Text]
9. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003[Medline]
10. Yannelli JR, Hyatt C, McConnell S, et al: Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 65:413-421, 1996[CrossRef][Medline]
11. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002[Abstract/Free Full Text]
12. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758, 2000[Abstract/Free Full Text]
13. Dudley ME, Wunderlich JR, Yang JC, et al: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243-251, 2002[Medline]
14. Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6:S11-S14, 2000 (suppl 1)[Medline]
15. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001[Abstract/Free Full Text]
16. Kawakami Y, Eliyahu S, Sakaguchi K, et al: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352, 1994[Abstract/Free Full Text]
17. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995[Abstract]
18. Dudley ME, Wunderlich J, Nishimura MI, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24:363-373, 2001[Medline]
19. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189-201, 1990[CrossRef][Medline]
20. Fetsch PA, Marincola FM, Filie A, et al: Melanoma-associated antigen recognized by T cells (MART-1): The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer 87:37-42, 1999[CrossRef][Medline]
21. Cormier JN, Hijazi YM, Abati A, et al: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75:517-524, 1998[CrossRef][Medline]
22. Huang J, el Gamil M, Dudley ME, et al: T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 172:6057-6064, 2004[Abstract/Free Full Text]
23. Gratwohl A, Brand R, Apperley J, et al: Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 100:3877-3886, 2002[Abstract/Free Full Text]
24. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003[Abstract/Free Full Text]
25. Overwijk WW, Lee DS, Surman DR, et al: Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 96:2982-2987, 1999[Abstract/Free Full Text]
26. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994[Abstract/Free Full Text]
27. Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T cell immunity against a persisting tumor/self-antigen requires CD4+ T dells and fails in the presence of naturally occurring T regulatory cells. J Immunol 174:2591-2601, 2005[Abstract/Free Full Text]
28. Ma J, Urba WJ, Si L, et al: Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33:2123-2132, 2003[CrossRef][Medline]
29. Mackall CL, Gress RE: Thymic aging and T-cell regeneration. Immunol Rev 160:91-102, 1997[CrossRef][Medline]
30. Rutella S, Pierelli L, Bonanno G, et al: Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 100:2562-2571, 2002[Abstract/Free Full Text]
31. Sloand EM, Kim S, Maciejewski JP, et al: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95:2269-2274, 2000[Abstract/Free Full Text]
32. Rosenberg SA, Yang JC, Robbins PF, et al: Cell transfer therapy for cancer: Lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26:385-393, 2003[Medline]
33. Yee C, Thompson JA, Byrd D, et al: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168-16173, 2002[Abstract/Free Full Text]
Submitted August 25, 2004;
accepted October 18, 2004.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
P. S. Woll, B. Grzywacz, X. Tian, R. K. Marcus, D. A. Knorr, M. R. Verneris, and D. S. Kaufman
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
Blood,
June 11, 2009;
113(24):
6094 - 6101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Brunstein, J. E. Wagner, D. J. Weisdorf, S. Cooley, H. Noreen, J. N. Barker, T. DeFor, M. R. Verneris, B. R. Blazar, and J. S. Miller
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity
Blood,
May 28, 2009;
113(22):
5628 - 5634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Rizzuto, T. Merghoub, D. Hirschhorn-Cymerman, C. Liu, A. M. Lesokhin, D. Sahawneh, H. Zhong, K. S. Panageas, M.-A. Perales, G. Altan-Bonnet, et al.
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response
J. Exp. Med.,
April 13, 2009;
206(4):
849 - 866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O. Kilinc, T. Gu, J. L. Harden, L. P. Virtuoso, and N. K. Egilmez
Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity
J. Immunol.,
April 1, 2009;
182(7):
4217 - 4225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Louis, K. Straathof, C. M. Bollard, C. Gerken, M. H. Huls, M. V. Gresik, M.-F. Wu, H. L. Weiss, A. P. Gee, M. K. Brenner, et al.
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
Blood,
March 12, 2009;
113(11):
2442 - 2450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Lopez, C. Pereda, G. Segal, L. Munoz, R. Aguilera, F. E. Gonzalez, A. Escobar, A. Ginesta, D. Reyes, R. Gonzalez, et al.
Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor {beta}-Expressing T Cells
J. Clin. Oncol.,
February 20, 2009;
27(6):
945 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Shu, C. G. Radu, S. M. Shelly, D. D. Vo, R. Prins, A. Ribas, M. E. Phelps, and O. N. Witte
Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen
Int. Immunol.,
February 1, 2009;
21(2):
155 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. AKIYAMA, K. MARUYAMA, S. TAI, M. KOMIYAMA, A. IIZUKA, M. TAKIKAWA, C. OHSHITA, A. YAMAMOTO, N. YAMAZAKI, Y. KIYOHARA, et al.
Characterization of a MAGE-1-derived HLA-A24 Epitope-specific CTL Line from a Japanese Metastatic Melanoma Patient
Anticancer Res,
February 1, 2009;
29(2):
647 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. van der Veken, M. Coccoris, E. Swart, J. H. F. Falkenburg, T. N. Schumacher, and M. H. M. Heemskerk
{alpha}{beta} T Cell Receptor Transfer to {gamma}{delta} T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo
J. Immunol.,
January 1, 2009;
182(1):
164 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. MARKEL, T. COHEN-SINAI, M. J. BESSER, K. OVED, O. ITZHAKI, R. SEIDMAN, A. J. TREVES, E. FRIDMAN, Y. KEISARI, Z. DOTAN, et al.
Preclinical Evaluation of Adoptive Cell Therapy for Patients with Metastatic Renal Cell Carcinoma
Anticancer Res,
January 1, 2009;
29(1):
145 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Parkhurst, J. Joo, J. P. Riley, Z. Yu, Y. Li, P. F. Robbins, and S. A. Rosenberg
Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells
Clin. Cancer Res.,
January 1, 2009;
15(1):
169 - 180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Dudley and S. A. Rosenberg
Clinical Trials Investigating Adoptive Cell Therapy Combined with Lymphodepletion for Patients with Advanced Cancer
ASCO Educational Book,
January 1, 2009;
2009(1):
516 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mackensen
Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy
ASCO Educational Book,
January 1, 2009;
2009(1):
521 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Brody, M. J. Goldstein, D. K. Czerwinski, and R. Levy
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors
Blood,
January 1, 2009;
113(1):
85 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Daud, R. C. DeConti, S. Andrews, P. Urbas, A. I. Riker, V. K. Sondak, P. N. Munster, D. M. Sullivan, K. E. Ugen, J. L. Messina, et al.
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
J. Clin. Oncol.,
December 20, 2008;
26(36):
5896 - 5903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C.R. Emtage, A. S.Y. Lo, E. M. Gomes, D. L. Liu, R. M. Gonzalo-Daganzo, and R. P. Junghans
Second-Generation Anti-Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation
Clin. Cancer Res.,
December 15, 2008;
14(24):
8112 - 8122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Boni, P. Muranski, L. Cassard, C. Wrzesinski, C. M. Paulos, D. C. Palmer, L. Gattinoni, C. S. Hinrichs, C.-C. Chan, S. A. Rosenberg, et al.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
Blood,
December 1, 2008;
112(12):
4746 - 4754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Cheung, M. J.P. DuPage, H. K. Dong, J. Chen, and T. Jacks
Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer
Cancer Res.,
November 15, 2008;
68(22):
9459 - 9468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al.
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
J. Clin. Oncol.,
November 10, 2008;
26(32):
5233 - 5239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yan, N. Himoudi, M. Pule, N. Sebire, E. Poon, A. Blair, O. Williams, and J. Anderson
Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy
Cancer Res.,
October 1, 2008;
68(19):
8058 - 8065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Tang, B. Grzywacz, H. Wang, N. Kataria, Q. Cao, J. E. Wagner, B. R. Blazar, J. S. Miller, and M. R. Verneris
Umbilical Cord Blood T Cells Express Multiple Natural Cytotoxicity Receptors after IL-15 Stimulation, but Only NKp30 Is Functional
J. Immunol.,
October 1, 2008;
181(7):
4507 - 4515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. de Witte, A. Jorritsma, A. Kaiser, M. D. van den Boom, M. Dokter, G. M. Bendle, J. B. A. G. Haanen, and T. N. M. Schumacher
Requirements for Effective Antitumor Responses of TCR Transduced T Cells
J. Immunol.,
October 1, 2008;
181(7):
5128 - 5136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zappasodi, M. Di Nicola, C. Carlo-Stella, R. Mortarini, A. Molla, C. Vegetti, S. Albani, A. Anichini, and A. M. Gianni
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells
Haematologica,
October 1, 2008;
93(10):
1523 - 1534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Weber
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Oncologist,
October 1, 2008;
13(suppl_4):
16 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Tatum, L. M. Mylin, S. J. Bender, M. A. Fischer, B. A. Vigliotti, M. J. Tevethia, S. S. Tevethia, and T. D. Schell
CD8+ T Cells Targeting a Single Immunodominant Epitope are Sufficient for Elimination of Established SV40 T Antigen-Induced Brain Tumors
J. Immunol.,
September 15, 2008;
181(6):
4406 - 4417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. N. Cooper
Test-driving CARs
Blood,
September 15, 2008;
112(6):
2172 - 2173.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood, H. A. Greisman, X. Qian, S. E. James, A. Raubitschek, S. J. Forman, et al.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Blood,
September 15, 2008;
112(6):
2261 - 2271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Rosenberg
Overcoming obstacles to the effective immunotherapy of human cancer
PNAS,
September 2, 2008;
105(35):
12643 - 12644.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. King, J. Waxman, and H. Stauss
Advances in tumour immunotherapy
QJM,
September 1, 2008;
101(9):
675 - 683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, and B. Savoldo
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia
Blood,
September 1, 2008;
112(5):
1876 - 1885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, et al.
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
Science,
August 15, 2008;
321(5891):
974 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Menard, F. Ghiringhelli, S. Roux, N. Chaput, C. Mateus, U. Grohmann, S. Caillat-Zucman, L. Zitvogel, and C. Robert
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
Clin. Cancer Res.,
August 15, 2008;
14(16):
5242 - 5249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Kaufman, H.-J. Lenz, J. Marshall, D. Singh, C. Garett, C. Cripps, M. Moore, M. von Mehren, R. Dalfen, W. J. Heim, et al.
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res.,
August 1, 2008;
14(15):
4843 - 4849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wei, A. B. Shreiner, N. Takeshita, L. Chen, W. Zou, and A. E. Chang
Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor {beta}
Cancer Res.,
July 1, 2008;
68(13):
5432 - 5438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. J. Finn
Cancer Immunology
N. Engl. J. Med.,
June 19, 2008;
358(25):
2704 - 2715.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al.
An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer
Cancer Res.,
June 15, 2008;
68(12):
4893 - 4901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda
Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers
Clin. Cancer Res.,
June 15, 2008;
14(12):
3966 - 3974.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Palmer, C.-C. Chan, L. Gattinoni, C. Wrzesinski, C. M. Paulos, C. S. Hinrichs, D. J. Powell Jr., C. A. Klebanoff, S. E. Finkelstein, R. N. Fariss, et al.
From the Cover: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
PNAS,
June 10, 2008;
105(23):
8061 - 8066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. Tumeh, C. G. Radu, and A. Ribas
PET Imaging of Cancer Immunotherapy
J. Nucl. Med.,
June 1, 2008;
49(6):
865 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Sebestyen, E. Schooten, T. Sals, I. Zaldivar, E. San Jose, B. Alarcon, S. Bobisse, A. Rosato, J. Szollosi, J. W. Gratama, et al.
Human TCR That Incorporate CD3{zeta} Induce Highly Preferred Pairing between TCR{alpha} and {beta} Chains following Gene Transfer
J. Immunol.,
June 1, 2008;
180(11):
7736 - 7746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. K. Darcy
IL-21 priming enhances T-cell immunotherapy
Blood,
June 1, 2008;
111(11):
5268 - 5269.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Blood,
June 1, 2008;
111(11):
5326 - 5333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Coccoris, E. Swart, M. A. de Witte, J. W. J. van Heijst, J. B. A. G. Haanen, K. Schepers, and T. N. M. Schumacher
Long-Term Functionality of TCR-Transduced T Cells In Vivo
J. Immunol.,
May 15, 2008;
180(10):
6536 - 6543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Clin. Cancer Res.,
May 15, 2008;
14(10):
3156 - 3167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Maury, C. Cordonnier, M. Kuentz, D. Klatzmann, and J. L. Cohen
Searching for factors to improve the antileukemic effect of donor lymphocyte infusion
Blood,
May 15, 2008;
111(10):
5256 - 5256.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach
Exuberated Numbers of Tumor-Specific T Cells Result in Tumor Escape
Cancer Res.,
May 1, 2008;
68(9):
3450 - 3457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine,
May 1, 2008;
233(5):
522 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili
Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors
Cancer Res.,
April 1, 2008;
68(7):
2436 - 2446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen
Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer
Cancer Res.,
April 1, 2008;
68(7):
2455 - 2462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Machlenkin, R. Uzana, S. Frankenburg, G. Eisenberg, L. Eisenbach, J. Pitcovski, R. Gorodetsky, A. Nissan, T. Peretz, and M. Lotem
Capture of Tumor Cell Membranes by Trogocytosis Facilitates Detection and Isolation of Tumor-Specific Functional CTLs
Cancer Res.,
March 15, 2008;
68(6):
2006 - 2013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fujita, X. Zhu, K. Sasaki, R. Ueda, K. L. Low, I. F. Pollack, and H. Okada
Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma
J. Immunol.,
February 15, 2008;
180(4):
2089 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Mirmonsef, G. Tan, G. Zhou, T. Morino, K. Noonan, I. Borrello, and H. I. Levitsky
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation
Blood,
February 15, 2008;
111(4):
2112 - 2121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Heimberger, W. Sun, S. F. Hussain, M. Dey, L. Crutcher, K. Aldape, M. Gilbert, S. J. Hassenbusch, R. Sawaya, B. Schmittling, et al.
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
Neuro-oncol,
February 1, 2008;
10(1):
98 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Marques, P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler
An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression
Blood,
February 1, 2008;
111(3):
1413 - 1419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Barber, T. Zhang, and C. L. Sentman
Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer
J. Immunol.,
January 1, 2008;
180(1):
72 - 78.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, et al.
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
Blood,
November 15, 2007;
110(10):
3564 - 3572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Yi, H. Nechushtan, W. J. Bowers, G. R. Walker, Y. Zhang, D. G. Pham, E. R. Podack, H. J. Federoff, K. A. Tolba, and J. D. Rosenblatt
Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity In vivo
Cancer Res.,
October 15, 2007;
67(20):
10027 - 10037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Kochenderfer and R. E. Gress
A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies
Experimental Biology and Medicine,
October 1, 2007;
232(9):
1130 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, and J. S. Weber
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Int. Immunol.,
October 1, 2007;
19(10):
1223 - 1234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Choi, Y. H. Kim, W. J. Kang, S. K. Lee, K. H. Kim, S. M. Shin, W. M. Yokoyama, T. Y. Kim, and B. S. Kwon
Mechanisms Involved in Synergistic Anticancer Immunity of Anti-4-1BB and Anti-CD4 Therapy
Cancer Res.,
September 15, 2007;
67(18):
8891 - 8899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lizee, M. A. Cantu, and P. Hwu
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5250 - 5255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell
Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5262 - 5270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al.
Toll-like Receptors in Tumor Immunotherapy
Clin. Cancer Res.,
September 15, 2007;
13(18):
5280 - 5289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. McDermott and M. B. Atkins
More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma
J. Clin. Oncol.,
September 1, 2007;
25(25):
3791 - 3793.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mizukami, T. Hanagiri, M. Yasuda, K. Kuroda, Y. Shigematsu, T. Baba, T. Fukuyama, Y. Nagata, T. So, Y. Ichiki, et al.
Antitumor Effect of Antibody against a SEREX-Defined Antigen (UOEH-LC-1) on Lung Cancer Xenotransplanted into Severe Combined Immunodeficiency Mice
Cancer Res.,
September 1, 2007;
67(17):
8351 - 8357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Matter, V. Pavelic, D. D. Pinschewer, S. Mumprecht, B. Eschli, T. Giroglou, D. von Laer, and A. F. Ochsenbein
Decreased Tumor Surveillance after Adoptive T-Cell Therapy
Cancer Res.,
August 1, 2007;
67(15):
7467 - 7476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Pittet, J. Grimm, C. R. Berger, T. Tamura, G. Wojtkiewicz, M. Nahrendorf, P. Romero, F. K. Swirski, and R. Weissleder
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
PNAS,
July 24, 2007;
104(30):
12457 - 12461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schlom, P. M. Arlen, and J. L. Gulley
Cancer Vaccines: Moving Beyond Current Paradigms
Clin. Cancer Res.,
July 1, 2007;
13(13):
3776 - 3782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hsu, S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P. D. Peng, X. Shen, T. J. Gomes, et al.
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
Blood,
June 15, 2007;
109(12):
5168 - 5177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor
J. Immunol.,
June 1, 2007;
178(11):
6752 - 6760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz
Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response
Blood,
June 1, 2007;
109(11):
4865 - 4876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhao, M. R. Parkhurst, Z. Zheng, C. J. Cohen, J. P. Riley, L. Gattinoni, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan
Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling
Cancer Res.,
March 15, 2007;
67(6):
2425 - 2429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al.
Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell
Clin. Cancer Res.,
March 15, 2007;
13(6):
1857 - 1867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dang, K. L. Knutson, V. Goodell, C. dela Rosa, L. G. Salazar, D. Higgins, J. Childs, and M. L. Disis
Tumor Antigen-Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming
Clin. Cancer Res.,
March 15, 2007;
13(6):
1883 - 1891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Lopez, C. Pereda, M. Ramirez, A. Mendoza-Naranjo, A. Serrano, A. Ferreira, R. Poblete, A. M. Kalergis, R. Kiessling, and F. Salazar-Onfray
Melanocortin 1 Receptor Is Expressed by Uveal Malignant Melanoma and Can Be Considered a New Target for Diagnosis and Immunotherapy
Invest. Ophthalmol. Vis. Sci.,
March 1, 2007;
48(3):
1219 - 1227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. F. Costa, K. Le Blanc, and B. Brodin
Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer
Stem Cells,
March 1, 2007;
25(3):
707 - 711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bracci, F. Moschella, P. Sestili, V. La Sorsa, M. Valentini, I. Canini, S. Baccarini, S. Maccari, C. Ramoni, F. Belardelli, et al.
Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration
Clin. Cancer Res.,
January 15, 2007;
13(2):
644 - 653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Riddell
Engineering Antitumor Immunity by T-Cell Adoptive Immunotherapy
Hematology,
January 1, 2007;
2007(1):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al.
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines
Blood,
January 1, 2007;
109(1):
365 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5576 - 5583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al.
Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells
Cancer Res.,
December 1, 2006;
66(23):
11447 - 11454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Montagna, R. Maccario, F. Locatelli, E. Montini, S. Pagani, F. Bonetti, L. Daudt, I. Turin, D. Lisini, C. Garavaglia, et al.
Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia
Blood,
December 1, 2006;
108(12):
3843 - 3850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
J. Clin. Oncol.,
November 1, 2006;
24(31):
5060 - 5069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Markel, R. Seidman, N. Stern, T. Cohen-Sinai, O. Izhaki, G. Katz, M. Besser, A. J. Treves, R. S. Blumberg, R. Loewenthal, et al.
Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions
J. Immunol.,
November 1, 2006;
177(9):
6062 - 6071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Stoklasek, K. S. Schluns, and L. Lefrancois
Combined IL-15/IL-15R{alpha} Immunotherapy Maximizes IL-15 Activity In Vivo
J. Immunol.,
November 1, 2006;
177(9):
6072 - 6080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Powell Jr., M. E. Dudley, K. A. Hogan, J. R. Wunderlich, and S. A. Rosenberg
Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
J. Immunol.,
November 1, 2006;
177(9):
6527 - 6539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Johnson, B. Heemskerk, D. J. Powell Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg
Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes
J. Immunol.,
November 1, 2006;
177(9):
6548 - 6559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al.
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6106 - 6115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hirano, M. O. Butler, Z. Xia, A. Berezovskaya, A. P. Murray, S. Ansen, S. Kojima, and L. M. Nadler
Identification of an immunogenic CD8+ T-cell epitope derived from {gamma}-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia
Blood,
October 15, 2006;
108(8):
2662 - 2668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al.
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Science,
October 6, 2006;
314(5796):
126 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-h. Lee, T. Kakinuma, J. Wang, H. Zhang, D. C. Palmer, N. P. Restifo, and S. T. Hwang
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Mol. Cancer Ther.,
October 1, 2006;
5(10):
2592 - 2599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sensi and A. Anichini
Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy
Clin. Cancer Res.,
September 1, 2006;
12(17):
5023 - 5032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4794 - 4803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Knutson, H. Lu, B. Stone, J. M. Reiman, M. D. Behrens, C. M. Prosperi, E. A. Gad, A. Smorlesi, and M. L. Disis
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
J. Immunol.,
August 1, 2006;
177(3):
1526 - 1533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Speiser, P. Baumgaertner, C. Barbey, V. Rubio-Godoy, A. Moulin, P. Corthesy, E. Devevre, P.-Y. Dietrich, D. Rimoldi, D. Lienard, et al.
A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination
J. Immunol.,
July 15, 2006;
177(2):
1338 - 1348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Chen, J. C. Valencia, B. Lai, G. Zhang, J. K. Paterson, F. Rouzaud, W. Berens, S. M. Wincovitch, S. H. Garfield, R. D. Leapman, et al.
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas
PNAS,
June 27, 2006;
103(26):
9903 - 9907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
TOP
ABSTRACT
INTRODUCTION
